Abstract
Direct nose-to-brain delivery of drugs and faster onset of action have made intra-nasal route a much sought-after alternative to conventional routes of drug delivery to the brain. Lamotrigine is used for the treatment and management of neuropathic pain, and in the present work, lamotrigine (LTG)-PLGA nanoparticles were developed for intra-nasal delivery. The LTG-PLGA nanoparticles were prepared using modified nanoprecipitation method via high-speed homogenization and ultra-sonication techniques. Entrapment efficiency (EE%) of developed LTG-PLGA-NPs was found to be 84.87 ± 1.2% with drug loading of 10.21 ± 0.89%. The particle size of developed nanoparticles was found to be 184.6 nm with PDI value of 0.082 and zeta potential of − 18.8 mV. Dissolution profiles were studied in PBS (pH 7.4), simulated nasal fluid, and simulated cerebrospinal fluid where almost complete release was observed within 5 h in CSF. In vitro, cytotoxicity was analyzed using MTT assay where dose-dependent cytotoxicity was observed for developed LTG-PLGA-NPs. In vitro cytokine analysis showed positive effects of LTG-PLGA-NPs as pro-inflammatory cytokine suppressors. Further, in vivo studies were performed for radiolabeled formulation and drug (99mTc-LTG-PLGA-NPs and 99mTc-LTG-aqueous) using Sprague Dawley rats where with the help of gamma scintigraphy studies, various routes of administration viz. oral, intra-nasal, and intra-venous were compared. Various pharmacokinetic parameters were evaluated using biodistribution studies to estimate the drug levels in blood and brain. For 99mTc-LTG-PLGA-NPs via intra-nasal route, drug targeting efficiency (DTE%) was found to be 129.81% and drug target organ transport (DTP%) to be 22.81% in brain with Cmax of 3.82%/g within Tmax 1.5 h. Thus, the developed PLGA nanoparticles for intra-nasal delivery provide a possible alternative for existing available drug formulation for neuropathic pain management.
Similar content being viewed by others
Abbreviations
- AEDs:
-
Antiepileptic drugs
- IL:
-
Interleukin
- I.N:
-
Intra-nasal
- I.V.:
-
Intra-venous
- LTG:
-
Lamotrigine
- PLGA:
-
(Poly(lactic-co-glycolic acid)
- NPs:
-
Nanoparticles
- DTE:
-
Drug target efficiency
- DTP:
-
Drug transport percentage
- TNF-α:
-
Tumor necrosis factor alpha
- IFN-γ:
-
Interferon gamma
- 99mTc:
-
Technetium-99m
References
Siddall PJ, McClelland JM, Rutkowski SB, et al. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain. 2003;103(3):249–57.
Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367(9522):1618–25.
Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain. 1999;82(3):263–74.
Hewitt DJ, McDonald M, Portenoy RK, Rosenfeld B, Passik S, Breitbart W. Pain syndromes and etiologies in ambulatory AIDS patients. Pain. 1997;70(2–3):117–23.
McNamara J. Drugs acting on the central nervous system. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 461–86.
Han HC, Lee DH, Chung JM. Characteristics of ectopic discharges in a rat neuropathic pain model. PAIN®. 2000;84(2–3):253–61.
Chong E, Dupuis LL. Therapeutic drug monitoring of lamotrigine. Ann Pharmacother. 2002;36(5):917–20.
Srichaiya A, Longchoopol C, Oo-Puthinan S, Sayasathid J, Sripalakit P, Viyoch J. Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. Clin Ther. 2008;30(10):1844–51.
Castel-Branco M, Lebre V, Falcao A, Figueiredo I, et al. Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats. Eur J Pharmacol. 2003;482(1–3):163–8.
Löscher W, Ganter M, Fassbender CP. Correlation between drug and metabolite concentrations in plasma and anesthetic action of ketamine in swine. Am J Vet Res. 1990;51(3):391–8.
Walker MC, Tong X, Perry H, Alavijeh MS, Patsalos PN. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br J Pharmacol. 2000;130(2):242–8.
Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9(3):S5.
Chaturvedi M, Kumar M, Pathak K. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2011;2(4):215–22.
Gentile P, Chiono V, Carmagnola I, Hatton P. An overview of poly (lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15(3):3640–59.
Bilati U, Allémann E, Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm. 2005;59(3):375–88.
Sharma D, Maheshwari D, Philip G, Rana R, Bhatia S, Singh M, et al. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design: in vitro and in vivo evaluation. Biomed Res Int. 2014;2014:1–14.
Lalani J, Patil S, Kolate A, et al. Protein-functionalized PLGA nanoparticles of lamotrigine for neuropathic pain management. AapsPharmscitech. 2015;16(2):413–27.
Shinde VR, Shelake MR, Shetty SS, Chavan-Patil AB, Pore YV, Late SG. Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique. J Pharm Pharmacol. 2008;60(9):1121–9.
Emami J, Ghassami N, Ahmadi F. Development and validation of a new HPLC method for determination of lamotrigine and related compounds in tablet formulations. J Pharm Biomed Anal. 2006;40(4):999–1005.
Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK. Scale up, optimization and stability analysis of curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnol. 2012;10(1):38.
Romero-Pérez A, García-García E, Zavaleta-Mancera A, Ramírez-Bribiesca JE, Revilla-Vázquez A, Hernández-Calva LM, et al. Designing and evaluation of sodium selenite nanoparticles in vitro to improve selenium absorption in ruminants. Vet Res Commun. 2010;34(1):71–9.
Martinac A, Filipović-Grčić J, Perissutti B, Voinovich D, Pavelić Ž. Spray-dried chitosan/ethylcellulose microspheres for nasal drug delivery: swelling study and evaluation of in vitro drug release properties. J Microencapsul. 2005;22(5):549–61.
Mohanraj K, Sethuraman S, Krishnan UM. Development of poly (butylene succinate) microspheres for delivery of levodopa in the treatment of Parkinson’s disease. J Biomed Mater Res B Appl Biomater. 2013;101(5):840–7.
Sharma A, Gupta S, Sarethy IP, Dang S, Gabrani R. Green tea extract: possible mechanism and antibacterial activity on skin pathogens. Food Chem. 2012;135(2):672–5.
Sharma Y, Bashir S, Khan MF, et al. Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice. Biochem Biophys Res Commun. 2017;487(1):54–61.
Kaur A, Saxena Y, Bansal R, Gupta S, Tyagi A, Sharma RK, et al. Intravaginal delivery of polyphenon 60 and curcumin nanoemulsion gel. AAPS PharmSciTech. 2017;18(6):2188–202.
Sharma D, Sharma RK, Sharma N, Gabrani R, Sharma SK, Ali J, et al. Nose-to-brain delivery of PLGA-diazepam nanoparticles. AAPS PharmSciTech. 2015;16(5):1108–21.
Rastogi R, Sultana Y, Aqil M, et al. Alginate microspheres of isoniazid for oral sustained drug delivery. Int J Pharm. 2007;334(1–2):71–7.
Keck JP, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002;63:3–11.
Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358(1–2):285–91.
Cojocaru V, Ranetti AE, Hinescu LG, et al. Formulation and evaluation of in vitro release kinetics of Na3CaDTPA decorporation agent embedded in microemulsion-based gel formulation for topical delivery. Farmacia. 2015;63(5):656–64.
Shen S, Wu Y, Liu Y, Wu D. High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomedicine. 2017;12:4085–109.
Zheng S, Xie Y, Li Y, et al. Development of high drug-loading nanomicelles targeting steroids to the brain. Int J Nanomedicine. 2014;9:55.
Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8(6):1481–93.
Singhvi G, Singh M. In-vitro drug release characterization models. Int J Pharm Stud Res. 2011;2(1):77–84.
Kim DH, Martin DC. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials. 2006;27(15):3031–7.
Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv. 2010;7(4):429–44.
Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–86.
Hamilton TA. Molecular basis of macrophage activation: from gene expression to phenotypic diversity. Macrophage. 2002;2:73–102.
Hines DJ, Choi HB, Hines RM, Phillips AG, MacVicar BA. Prevention of LPS-induced microglia activation, cytokine production and sickness behavior with TLR4 receptor interfering peptides. PLoS One. 2013;8(3):e60388.
Murray CL, Skelly DT, Cunningham C. Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1β and IL-6. J Neuroinflammation. 2011;8(1):50.
Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503–8.
Liu W, Wu YH, Zhang L, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8(10):17362.
Yan Y, Guo TM, Zhu C. Effects of non-steroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis. Biochem Cell Biol. 2018;96:450–6.
Nigam K, Kaur A, Tyagi A, Manda K, Gabrani R, Dang S. Baclofen-loaded poly (d, l-lactide-co-glycolic acid) nanoparticles for neuropathic pain management: in vitro and in vivo evaluation. Rejuvenation Res 2018. https://doi.org/10.1089/rej.2018.2119.
Acknowledgements
The authors would like to acknowledge Jaypee Institute of Information Technology, Noida, and Institute of Nuclear Medicine & Allied Sciences, Delhi, for providing basic infrastructural support to carry out the project. The authors would like to thank Dr. A. Panda, National Institute of Immunology, Delhi, and Dr. M. Kalia, Translational Health Science And Technology Institute, Faridabad, for providing required resources for completion of this work.
Author information
Authors and Affiliations
Contributions
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.
Corresponding author
Ethics declarations
All institutional and national guidelines for the care and use of laboratory animals were followed.
Conflict of interest
The authors declare that there is no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nigam, K., Kaur, A., Tyagi, A. et al. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. Drug Deliv. and Transl. Res. 9, 879–890 (2019). https://doi.org/10.1007/s13346-019-00622-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13346-019-00622-5